Latest & greatest articles for estradiol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on estradiol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on estradiol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for estradiol

41. Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate tablets)

Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate tablets) Drug Approval Package: Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate) NDA #022501 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets, and ferrous fumarate tablets

2010 FDA - Drug Approval Package

42. Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium)

Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) Drug Approval Package: Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) NDA #022532 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Beyaz (drospirenone/ethinyl estradiol/levomefolate calcium and levomefolate calcium) tablets Company: Bayer HealthCare Pharmaceuticals Inc. Application No.: 022532 Approval Date: 09/24/2010 Persons

2010 FDA - Drug Approval Package

43. Subcutaneous implantation of estradiol pellets for postmenopausal disorders

Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Subcutaneous implantation of estradiol pellets for postmenopausal disorders Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Subcutaneous implantation of estradiol pellets for postmenopausal disorders. Lansdale

2010 Health Technology Assessment (HTA) Database.

44. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. (Abstract)

Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. To clarify whether adding E(2) to standard luteal P supplementation is beneficial both in GnRH agonist and antagonist IVF cycles.Meta-analysis of nine randomized controlled trials.University hospital center for reproductive medicine and IVF.None.Clinical pregnancy rate (PR) per patient, clinical PR per embryo transfer (ET), implantation rate, ongoing PR per patient, clinical abortion

2010 Fertility and sterility

45. Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study (Full text)

Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study To investigate the relationship between total estradiol (E2) levels and 9-year mortality in older postmenopausal women not taking hormone replacement therapy (HRT).Population-based study of persons living in the Chianti geographic area (Tuscany, Italy).Community.A representative sample of 509 women aged 65 and older with measures of total E2.Serum total E2 was measured

2009 EvidenceUpdates PubMed abstract

46. Circulating estradiol and mortality in men with systolic chronic heart failure. (Full text)

Circulating estradiol and mortality in men with systolic chronic heart failure. Androgen deficiency is common in men with chronic heart failure (HF) and is associated with increased morbidity and mortality. Estrogens are formed by the aromatization of androgens; therefore, abnormal estrogen metabolism would be anticipated in HF.To examine the relationship between serum concentration of estradiol and mortality in men with chronic HF and reduced left ventricular ejection fraction (LVEF (...) ).A prospective observational study at 2 tertiary cardiology centers (Wroclaw and Zabrze, Poland) of 501 men (mean [SD] age, 58 [12] years) with chronic HF, LVEF of 28% (SD, 8%), and New York Heart Association [NYHA] classes 1, 2, 3, and 4 of 52, 231, 181, and 37, respectively, who were recruited between January 1, 2002, and May 31, 2006. Cohort was divided into quintiles of serum estradiol (quintile 1, < 12.90 pg/mL; quintile 2, 12.90-21.79 pg/mL; quintile 3, 21.80-30.11 pg/mL; quintile 4, 30.12-37.39 pg/mL

2009 JAMA PubMed abstract

47. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy (Abstract)

Breast cancer risk in postmenopausal women using estradiol-progestogen therapy To estimate the risk for breast cancer in Finnish women using postmenopausal estradiol (E2)-progestogen therapy.All Finnish women over 50 years using E2-progestogen therapy for at least 6 months in 1994-2005 (N=221,551) were identified from the national medical reimbursement register and followed up for breast cancer incidence (n=6,211 cases) through the Finnish Cancer Registry to the end of 2005. The risk for breast

2009 EvidenceUpdates

48. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. (Full text)

Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy.To determine whether 6 mg of estradiol (daily) is a viable therapy for postmenopausal women with advanced aromatase inhibitor-resistant hormone receptor (...) -positive breast cancer.A phase 2 randomized trial of 6 mg vs 30 mg of oral estradiol used daily (April 2004-February 2008 [enrollment closed]). Eligible patients (66 randomized) had metastatic breast cancer treated with an aromatase inhibitor with progression-free survival (> or = 24 wk) or relapse (after > or = 2 y) of adjuvant aromatase inhibitor use. Patients at high risk of estradiol-related adverse events were excluded. Patients were examined after 1 and 2 weeks for clinical and laboratory

2009 JAMA Controlled trial quality: predicted high PubMed abstract

49. Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy

Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy | Therapeutics Initiative Independent Healthcare Evidence > > Ethinyl estradiol 30 µg and levonorgestrel 150 µg (Seasonale) for prevention of pregnancy This is the summary of a systematic review assessing the comparative safety and efficacy of Seasonale (ethinyl estradiol 30 μg, levonorgestrel 150 μg, extended 91-day (...) cycle), in the prevention of pregnancy in sexually active women of reproductive age. Drug This oral contraceptive (OC) combines an estrogen, ethinyl estradiol (EE) 30 μg, and a progestin, levonorgestrel (LNG)150 μg, commonly contained in other OCs in Canada. Duration of active treatment for this product is 84 days, followed by 7 days of placebo. It is the only product available in Canada that is specifically formulated for extended-cycle use. The aim of this formulation, in addition to pregnancy

2009 Therapeutics Letter

50. GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. (Full text)

GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. With large amounts of public expression microrray data being generated by multiple laboratories, it is a significant task for the bench researcher to routinely identify available datasets, and then to evaluate the collective evidence across these datasets for regulation of a specific gene in a given system. 17beta-Estradiol stimulation of MCF-7 (...) ) that provides the user a consensus for each gene in the system. We conducted a weighted meta-analysis encompassing over 13,000 genes across 10 independent published datasets addressing the effect of 17beta-estradiol on MCF-7 cells at early (3-4 hours) and late (24 hours) time points. In a literature survey of 58 genes previously shown to be regulated by 17beta-estradiol in MCF-7 cells, the meta-analysis combined the statistical power of the underlying datasets to call regulation of these genes with nearly

2009 Cancer research PubMed abstract

51. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. (Abstract)

The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. To investigate the effect of luteal E(2) supplementation on the pregnancy rate of IVF/intracytoplasmic sperm injection (ICSI) cycles.A systematic review and meta-analysis of all the randomized controlled trials (RCTs).Tertiary referral center for reproductive medicine and IVF.Women undergoing IVF or ICSI using the GnRH agonist or GnRH antagonist (...) protocol with hMG or FSH for controlled ovarian hyperstimulation.Progesterone (P4) alone or combined with estradiol valerate for luteal phase support.Pregnancy and clinical pregnancy rates per ET.An electronic search was conducted targeting all reports published between January 1960 and March 2007. Ten RCTs met the criteria for inclusion in the meta-analysis. There were no statistically significant differences with regard to the main outcome measures, ongoing pregnancy rate per ET, or implantation rate

2008 Fertility and sterility

52. Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial (Abstract)

Low-dose estradiol spray to treat vasomotor symptoms: a randomized controlled trial To investigate the safety and efficacy of a transdermal estradiol (E2) spray in women with postmenopausal vasomotor symptoms.A randomized, double-blind, placebo-controlled, multicenter, parallel-group clinical trial was conducted. Postmenopausal women (N=454) with at least eight moderate-to-severe hot flushes per day applied daily, one, two, or three E2 (90 microliter spray contains 1.53 mg E2) or matching

2008 EvidenceUpdates Controlled trial quality: predicted high

53. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women (Abstract)

The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women This study was undertaken to examine the effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women.Analysis of data from a multicenter, randomized, double-blind, placebo-controlled trial of a 0.014 mg/day transdermal estradiol patch in 417 women aged 60 to 80 years. Sexual function was assessed by self-administered questionnaires at baseline and 4, 12, and 24 months (...) . A linear effects model was used to assess treatment effects using data from all on-study assessments.Women randomly assigned to estradiol had a 4.3 point greater improvement in the vaginal pain/dryness domain relative to placebo (95% CI = 0.3-8.4, P = .04). No significant differences in frequency of sexual activity or other sexual function domains (desire, satisfaction, problems, or orgasm) were observed between treatment groups (P > or = .10 for all).Ultralow-dose estradiol resulted in modest

2008 EvidenceUpdates Controlled trial quality: predicted high

54. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis

The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

55. Lowest Effective Transdermal 17{beta}-Estradiol Dose for Relief of Hot Flushes in Postmenopausal Women: A Randomized Controlled Trial. (Abstract)

Lowest Effective Transdermal 17{beta}-Estradiol Dose for Relief of Hot Flushes in Postmenopausal Women: A Randomized Controlled Trial. OBJECTIVE: To investigate the efficacy of micro-dose transdermal estrogen in relieving menopausal vasomotor symptoms. METHODS: A randomized, double-blind, placebo-controlled, multi-center trial. Healthy postmenopausal women with at least seven moderate or severe hot flushes per day for at least 1 week, or at least 50 per week, applied transdermal patches (...) with a nominal delivery of 0.023 mg/d 17beta-estradiol and 0.0075 mg/d levonorgestrel (low-dose E2/levonorgestrel; n=145), 0.014 mg/d E2 (micro-dose; n=147), or placebo (n=133) for 12 weeks. The coprimary efficacy variables were the mean changes from baseline in frequency and severity of moderate and severe hot flushes at the week 4 and 12 endpoints. RESULTS: At the week 12 endpoint, mean weekly frequencies of moderate and severe hot flushes were significantly reduced compared with placebo with low-dose E2

2007 EvidenceUpdates Controlled trial quality: predicted high

56. Yaz (drospirenone 3mg/ethinyl estradiol 0.02mg)

Yaz (drospirenone 3mg/ethinyl estradiol 0.02mg) Drug Approval Package: YAZ (drospirenone 3mg/ethinyl estradiol 0.02mg) NDA #022045 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - YAZ (drospirenone 3mg/ethinyl estradiol 0.02mg) Tablets Company: Berlex, Inc. Application No.: 022045 Approval Date: 01/26/2007 (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: February 22, 2008 Updated: October 3, 2011 Note: Documents in PDF format require

2007 FDA - Drug Approval Package

57. Etonogestrel/ethinyl estradiol

Etonogestrel/ethinyl estradiol Common Drug Review CEDAC Meeting – October 18, 2006 Page 1 of 2 Notice of CEDAC Final Recommendation – November 29, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION ETONOGESTREL/ETHINYL ESTRADIOL (NuvaRing TM - Organon Canada Ltd.) Description: NuvaRing TM is a contraceptive vaginal ring containing two active components, etonogestrel and ethinyl estradiol. Dosage Forms: NuvaRing TM contains 11.4 mg etonogestrel and 2.6 mg ethinyl estradiol (...) and releases, on average, 120 µg/day of etonogestrel and 15 µg/day of ethinyl estradiol over a three week period of use. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that NuvaRing TM be listed on the condition that the amount paid by drug plans for NuvaRing TM per cycle not exceed the current maximum paid for oral contraceptives. Reasons for the Recommendation: 1. The Committee considered a systematic review of randomized controlled trials (RCTs) of at least six months

2007 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

58. Yaz (drospirenone/ethinyl estradiol) for Oral Contraception and Premenstrual Dysphoric Disorder

Yaz (drospirenone/ethinyl estradiol) for Oral Contraception and Premenstrual Dysphoric Disorder Drug Approval Package: Yaz (drospirenone/ethinyl estradiol) NDA #021873 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Yaz (drospirenone/ethinyl estradiol) for Oral Contraception and Premenstrual Dysphoric Disorder Company: Berlex, Inc. NDA: 021873 Approval Date: 10/4/2006 (PDF) (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2006 FDA - Drug Approval Package

59. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. (Abstract)

Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Based on the potential risks of post-menopausal hormone therapy (HT) found by the Women's Health Initiative, guidelines for HT now recommend use of the lowest effective dose and shortest treatment duration consistent with individual treatment goals. Current (2003) guidance established by the US Food and Drug (...) Administration (FDA) recommends that clinical assessments of HT include women with more frequent and more intense vasomotor symptoms than previously studied. Therefore, this analysis was conducted to further assess the efficacy of a low-dose combination of norethindrone acetate and ethinyl estradiol (NA/EE) previously assessed in dose-ranging studies, while meeting conservative FDA trial design and analysis criteria.The aim of this post hoc analysis and overview was to present data on the efficacy

2006 Clinical therapeutics

60. drospirenone /ethinyl estradiol

drospirenone /ethinyl estradiol CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION DROSPIRENONE / ETHINYL ESTRADIOL (Yasmin ® – Berlex Canada Inc.) Description: Yasmin® is a monophasic combination of drospirenone 3 mg and ethinyl estradiol 0.03 mg, approved for oral conception control. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that the combination of drospirenone 3 mg and ethinyl estradiol 0.03 mg be listed. Reasons for the recommendation: 1. Efficacy (...) is similar to currently available monophasic combination oral contraceptives with different progestogen but same ethinyl estradiol concentration. 2. Safety appears to be similar to currently available monophasic combination oral contraceptives with different progestogen but same ethinyl estradiol concentration. 3. Cost is similar compared to currently available monophasic combination oral contraceptives with different progestogen but same ethinyl estradiol concentration. Of Note: 1. Drosperinone is a new

2005 Canadian Agency for Drugs and Technologies in Health - Common Drug Review